NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor. Tumor Treating Fields therapy uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.
What is NovoTTF?
What is it? The NovoTTF-100L System is the first device indicated to be used in conjunction with a standard two-drug chemotherapy to treat patients with a cancerous tumor, malignant pleural mesothelioma (MPM) that is unable to be removed via surgery (unresectable).
Is optune FDA approved?
Optune has been FDA approved for the treatment of recurrent GBM and has received CE mark for the treatment of both recurrent and newly diagnosed GBM. The device has been available commercially in the European Union (EU) 42009 and in the US since October 2011.
What does novocure Ltd do?
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.
Is novocure FDA approved?
Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for its LUNAR trial to 276 patients with 12 months follow-up.
What is optune Lua?
Optune Lua is a wearable, portable, FDA-approved device indicated for the treatment of adult patients, with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used together with standard chemotherapy (pemetrexed and platinum-based chemotherapy).
What drugs are approved for glioblastoma?
Outside of TMZ, there are four drugs and one device FDA-approved for the treatment of high-grade gliomas: lomustine, intravenous carmustine, carmustine wafer implants, bevacizumab, and tumor treatment fields (Table 4) [25,26,27].
What is optune Novocure?
Optune Lua, formerly known as NovoTTF-100L, is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years. ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Optune Lua is the brand name for the NovoTTF-100L System in malignant pleural mesothelioma (MPM).
Is Novocure an Israeli company?
Novocure was founded in Israel, and its headquarters and R&D setup are currently located in Haifa, while the company’s marketing operations are in the US. The company is managed by Israeli CEO Asaf Danziger, and its executive chairman is Bill Doyle of the US. The technology was invented by Prof.
Who makes novocure?
In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the …
Where is novocure located?
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, Novocure has offices in Germany, Switzerland, Japan and Israel.
What does novottf stand for?
Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division. Methods: Phase III trial of chemotherapy-free treatment of NovoTTF (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent glioblastoma.
How do I use The NovoTTF-100A?
The NovoTTF-100A System is a portable device. It produces electric fields, called tumor treatment fields (“TTFields”). Transducer arrays connected to the device deliver TTFields to your head. The TTFields are intended to destroy brain cancer cells. The device and battery are carried in a shoulder bag. You should use them all the time.
Is the Novocure ttf-100l approved by the FDA?
ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM).
What is the life expectancy of a NovoTTF-100A patient?
Patients using the NovoTTF-100A System lived similar amount of time compared to patients using cancer drugs. In the clinical study, half of the patients in both groups lived for more than 6.4 months. 22 out of each 100 patients lived for one year or longer. Patients using the NovoTTF-100A System had a better quality of life (see Section 7 below).
